Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mediastinal Neoplasms | 2 | 2016 | 51 | 0.900 |
Why?
|
| Radiotherapy, Conformal | 2 | 2017 | 74 | 0.610 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2018 | 63 | 0.540 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 27 | 0.510 |
Why?
|
| Thymoma | 1 | 2017 | 36 | 0.500 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 155 | 0.490 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 118 | 0.490 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2018 | 152 | 0.460 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 105 | 0.440 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 253 | 0.430 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 132 | 0.430 |
Why?
|
| Aortic Valve | 1 | 2018 | 365 | 0.430 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 127 | 0.430 |
Why?
|
| Postoperative Care | 1 | 2017 | 288 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 192 | 0.380 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 543 | 0.380 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 741 | 0.360 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 8265 | 0.350 |
Why?
|
| Brachytherapy | 3 | 2018 | 134 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1953 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 965 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 1462 | 0.320 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 5408 | 0.300 |
Why?
|
| Databases, Factual | 4 | 2018 | 1486 | 0.270 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 1325 | 0.250 |
Why?
|
| Aged | 11 | 2018 | 25913 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2018 | 11679 | 0.200 |
Why?
|
| Middle Aged | 11 | 2018 | 35875 | 0.190 |
Why?
|
| Young Adult | 5 | 2018 | 14105 | 0.160 |
Why?
|
| Propensity Score | 3 | 2016 | 367 | 0.150 |
Why?
|
| Prognosis | 3 | 2018 | 4282 | 0.150 |
Why?
|
| Radiotherapy Dosage | 2 | 2017 | 289 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2018 | 23 | 0.140 |
Why?
|
| England | 1 | 2018 | 111 | 0.140 |
Why?
|
| Adult | 8 | 2018 | 40449 | 0.140 |
Why?
|
| SEER Program | 2 | 2018 | 224 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 974 | 0.140 |
Why?
|
| Registries | 2 | 2018 | 2385 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 96 | 0.130 |
Why?
|
| Radial Artery | 1 | 2018 | 70 | 0.130 |
Why?
|
| Survival Rate | 3 | 2017 | 2089 | 0.130 |
Why?
|
| Angiography | 1 | 2018 | 208 | 0.130 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 61 | 0.130 |
Why?
|
| Male | 9 | 2018 | 72315 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 171 | 0.120 |
Why?
|
| Female | 9 | 2018 | 78271 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2018 | 17066 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1266 | 0.120 |
Why?
|
| Time Factors | 2 | 2018 | 7173 | 0.120 |
Why?
|
| Datasets as Topic | 1 | 2016 | 122 | 0.120 |
Why?
|
| Rituximab | 1 | 2016 | 209 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 237 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 206 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2016 | 239 | 0.100 |
Why?
|
| Risk Factors | 2 | 2018 | 10779 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1306 | 0.090 |
Why?
|
| Humans | 11 | 2018 | 144759 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1382 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1720 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 727 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 947 | 0.090 |
Why?
|
| United States | 4 | 2017 | 15966 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2016 | 653 | 0.080 |
Why?
|
| Adolescent | 3 | 2018 | 22428 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1356 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 222 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2452 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 83 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 421 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 108 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 91 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 161 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 307 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 645 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 589 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1326 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 3333 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1560 | 0.020 |
Why?
|
| Colorado | 1 | 2015 | 4564 | 0.010 |
Why?
|